ADVENTRX Pharmaceuticals to Report Fourth Quarter and Full Year 2006 Financial Results on March 15, 2007
March 07 2007 - 6:00AM
PR Newswire (US)
- Webcast Discussion With Management Scheduled for March 15, 2007 -
SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) today announced it will release
fourth quarter and full year 2006 financial results after the
financial markets close on Thursday, March 15, 2007. ADVENTRX
management will host an investment-community conference call to
discuss the results and provide a corporate update on Thursday,
March 15, 2007 at 4:30 p.m. Eastern Time. Evan M. Levine, Chief
Executive Officer and Gregory P. Hanson, Senior Vice President and
Chief Financial Officer are scheduled to lead the call and will be
joined by other members of the Company's senior management to
discuss the quarter's and year's results and to take investors'
questions. Those interested in listening to the conference call
live via the Internet may do so by visiting the "Investors" section
of ADVENTRX's website at http://www.adventrx.com/. Replays of the
webcast will be available for 30 days, and a phone replay will be
available through April 16, 2007 by dialing 888-203-1112 and
entering the passcode 5166464. About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The
Company seeks to improve the performance and safety of existing
treatments by addressing significant problems, such as drug
metabolism and bioavailability, excessive toxicity and treatment
resistance. The Company's lead product candidate, ANX-510
(CoFactor), is in pivotal Phase III and Phase IIb clinical trials
for the treatment of metastatic colorectal cancer, as well as in a
Phase II clinical trial for the treatment of advanced breast
cancer. More information can be found on ADVENTRX's web site at
http://www.adventrx.com/. Forward Looking Statement ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors that, if they do not materialize or prove to be accurate,
could cause ADVENTRX's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. Such forward-looking statements are made based on
management's current expectations and beliefs and should not be
regarded as a statement or representation by ADVENTRX that any of
its plans, including its anticipated milestones, will be achieved
on time or at all. The potential risks and uncertainties that could
cause actual results to differ materially include, but are not
limited to: the risk that ADVENTRX will be unable to raise
sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones; the potential to
attract a strategic partner and the terms of any related
transaction; the ability to timely enroll subjects in ADVENTRX's
current and anticipated clinical trials; the potential for CoFactor
and ADVENTRX's other product candidates to receive regulatory
approval for one or more indications on a timely basis or at all,
and the uncertain process of seeking regulatory approval; other
difficulties or delays in developing, testing, manufacturing and
marketing of and obtaining regulatory approval for CoFactor or
ADVENTRX's other product candidates; the potential for regulatory
authorities to require additional preclinical work or other
clinical requirements to support regulatory filings; the scope and
validity of patent protection for CoFactor and ADVENTRX's other
product candidates; and other risks and uncertainties more fully
described in ADVENTRX's press releases and periodic filings with
the Securities and Exchange Commission. ADVENTRX's public filings
with the Securities and Exchange Commission are available at
http://www.sec.gov/. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date when made. All forward-looking statements are qualified in
their entirety by this cautionary statement and ADVENTRX assumes no
obligation to revise or update any forward-looking statement,
including as set forth in this press release, to reflect events or
circumstances arising after the date on which it was made.
DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors,
Ioana C. Hone of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866;
or Media, Amy Martini of WeissComm Partners, +1-212-301-7233, for
ADVENTRX Pharmaceuticals, Inc. Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024